Rett is effectively dead. People need to get used to it. Acadia is increasing the use of Trofinetide in major markets, which means fewer and fewer patients available for a large clinical trial. They were first to market, admittedly with a less than stellar drug, but first to market is hard to overcome. Missling wasted precious time and resources by spreading himself too thin chasing AD and PDD. As I’ve said for a long time, he should have focused on rare diseases from the start like he once said he intended to do. Remember when he held up Alexion as his model for Anavex? Instead, he let his ego take control and went after AD and PDD.
I guess schizophrenia is the new Rett, though it’ll take years to develop.
In reality, we’re basically back to Square 1. Oh well, maybe Blarcamesine can be developed as a sleep aid for 3 cents a day. That would make shareholders rich! (Sarc)
DOG bless,
News 
Market Data 
Discover 
AI
